Prothena (PRTA) Competitors $10.35 +0.30 (+2.99%) Closing price 04:00 PM EasternExtended Trading$10.34 -0.01 (-0.10%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. OCUL, ANIP, VERA, TWST, DYN, APGE, COGT, TLRY, ABCL, and IMCRShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Dyne Therapeutics Apogee Therapeutics Cogent Biosciences Tilray Brands AbCellera Biologics Immunocore Prothena (NASDAQ:PRTA) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Which has stronger valuation & earnings, PRTA or OCUL? Prothena has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$135.16M4.12-$122.31M-$5.64-1.84Ocular Therapeutix$56.66M36.39-$193.51M-$1.28-9.26 Which has more volatility and risk, PRTA or OCUL? Prothena has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Do insiders and institutionals believe in PRTA or OCUL? 97.1% of Prothena shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 10.0% of Prothena shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor PRTA or OCUL? In the previous week, Ocular Therapeutix had 12 more articles in the media than Prothena. MarketBeat recorded 20 mentions for Ocular Therapeutix and 8 mentions for Prothena. Prothena's average media sentiment score of 0.83 beat Ocular Therapeutix's score of 0.55 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PRTA or OCUL more profitable? Ocular Therapeutix has a net margin of -382.51% compared to Prothena's net margin of -2,929.30%. Prothena's return on equity of -62.17% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Prothena-2,929.30% -62.17% -54.43% Ocular Therapeutix -382.51%-71.92%-49.36% Do analysts prefer PRTA or OCUL? Prothena currently has a consensus price target of $20.50, indicating a potential upside of 98.07%. Ocular Therapeutix has a consensus price target of $22.63, indicating a potential upside of 90.93%. Given Prothena's higher possible upside, equities analysts clearly believe Prothena is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryProthena and Ocular Therapeutix tied by winning 8 of the 16 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$557.14M$3.33B$6.04B$10.46BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-1.8422.2285.3127.07Price / Sales4.12445.32589.44190.44Price / CashN/A44.9825.7330.17Price / Book1.1410.3812.666.69Net Income-$122.31M-$52.31M$3.31B$276.03M7 Day Performance4.97%0.59%-0.44%-1.13%1 Month Performance26.07%13.90%8.70%6.49%1 Year Performance-39.90%28.95%76.70%34.41% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.1278 of 5 stars$10.35+3.0%$20.50+98.1%-41.6%$557.14M$135.16M-1.84130OCULOcular Therapeutix3.9066 of 5 stars$10.97-3.9%$22.13+101.7%+20.4%$1.99B$56.66M-8.57230Insider TradeAnalyst RevisionANIPANI Pharmaceuticals3.8828 of 5 stars$92.06+2.7%$97.29+5.7%+57.1%$1.95B$614.38M-119.56600VERAVera Therapeutics2.3322 of 5 stars$30.94+2.7%$63.00+103.6%-29.6%$1.92BN/A-8.6440TWSTTwist Bioscience3.7771 of 5 stars$31.85+2.5%$48.90+53.5%-29.9%$1.88B$312.97M-21.97990DYNDyne Therapeutics3.5623 of 5 stars$12.65-3.1%$34.07+169.3%-58.3%$1.86BN/A-3.28100Analyst DowngradeAPGEApogee Therapeutics3.0683 of 5 stars$39.82-0.2%$92.63+132.6%-7.9%$1.84BN/A-9.6491COGTCogent Biosciences1.9445 of 5 stars$15.90+0.9%$20.00+25.8%+44.6%$1.79BN/A-8.9380High Trading VolumeTLRYTilray Brands2.4441 of 5 stars$1.58-2.5%$1.94+22.6%+5.5%$1.78B$210.48M-0.682,842Earnings ReportAnalyst UpgradeGap UpABCLAbCellera Biologics2.3881 of 5 stars$5.87-0.5%$8.00+36.3%+113.5%$1.76B$28.83M-10.67500IMCRImmunocore2.4314 of 5 stars$34.01-0.6%$56.89+67.3%+4.2%$1.72B$310.20M-85.03320 Related Companies and Tools Related Companies Ocular Therapeutix Competitors ANI Pharmaceuticals Competitors Vera Therapeutics Competitors Twist Bioscience Competitors Dyne Therapeutics Competitors Apogee Therapeutics Competitors Cogent Biosciences Competitors Tilray Brands Competitors AbCellera Biologics Competitors Immunocore Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
